Display options
Cite
Inchaurraga L, Martínez-López AL, Abdulkarim M, et al. Modulation of the fate of zein nanoparticles by their coating with a Gantrez® AN-thiamine polymer conjugate. Int J Pharm X. 2019;1:100006doi: 10.1016/j.ijpx.2019.100006.
Inchaurraga, L., Martínez-López, A. L., Abdulkarim, M., Gumbleton, M., Quincoces, G., Peñuelas, I., Martin-Arbella, N., & Irache, J. M. (2019). Modulation of the fate of zein nanoparticles by their coating with a Gantrez® AN-thiamine polymer conjugate. International journal of pharmaceutics: X, 1100006. https://doi.org/10.1016/j.ijpx.2019.100006
Inchaurraga, Laura, et al. "Modulation of the fate of zein nanoparticles by their coating with a Gantrez® AN-thiamine polymer conjugate." International journal of pharmaceutics: X vol. 1 (2019): 100006. doi: https://doi.org/10.1016/j.ijpx.2019.100006
Inchaurraga L, Martínez-López AL, Abdulkarim M, Gumbleton M, Quincoces G, Peñuelas I, Martin-Arbella N, Irache JM. Modulation of the fate of zein nanoparticles by their coating with a Gantrez® AN-thiamine polymer conjugate. Int J Pharm X. 2019 Jan 25;1:100006. doi: 10.1016/j.ijpx.2019.100006. eCollection 2019 Dec. PMID: 31517271; PMCID: PMC6733281.
Copy Download .nbib Format: NLM
Share it on

Int J Pharm X. 2019 Jan 25;1:100006. doi: 10.1016/j.ijpx.2019.100006. eCollection 2019 Dec.

Modulation of the fate of zein nanoparticles by their coating with a Gantrez® AN-thiamine polymer conjugate.

International journal of pharmaceutics: X

Laura Inchaurraga, Ana L Martínez-López, Muthanna Abdulkarim, Mark Gumbleton, Gemma Quincoces, Ivan Peñuelas, Nekane Martin-Arbella, Juan M Irache

Affiliations

  1. NANO-VAC Research Group, Department of Chemistry and Pharmaceutical Technology, University of Navarra, Spain.
  2. School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK.
  3. Radiopharmacy Unit, Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, Spain.

PMID: 31517271 PMCID: PMC6733281 DOI: 10.1016/j.ijpx.2019.100006

Abstract

The aim of this work was to evaluate the mucus-permeating properties of nanocarriers using zein nanoparticles (NPZ) coated with a Gantrez® AN-thiamine conjugate (GT). NPZ were coated by incubation at different GT-to-zein ratios: 2.5% coating with GT (GT-NPZ1), 5% (GT-NPZ2) and 10% (GT-NPZ3). During the process, the GT conjugate formed a polymer layer around the surface of zein nanoparticles. For GT-NPZ2, the thickness of this corona was estimated between 15 and 20 nm. These nanocarriers displayed a more negative zeta potential than uncoated NPZ. The diffusivity of nanoparticles was evaluated in pig intestinal mucus by multiple particle tracking analysis. GT-NPZ2 displayed a 28-fold higher diffusion coefficient within the mucus layer than NPZ particles. These results align with

Keywords: Coating; Mucus permeating; Nanoparticles; Oral delivery; Thiamine; Zein

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare that they

References

  1. J Biomed Mater Res. 2000 Jun 15;50(4):557-65 - PubMed
  2. J Pharm Sci. 2000 Jul;89(7):850-66 - PubMed
  3. J Control Release. 2001 Apr 2;71(2):203-11 - PubMed
  4. Int J Pharm. 2002 Aug 21;242(1-2):129-36 - PubMed
  5. J Control Release. 2003 Apr 14;89(1):19-30 - PubMed
  6. Biotechnol Prog. 2004 May-Jun;20(3):851-7 - PubMed
  7. Amino Acids. 2005 Feb;28(1):99-103 - PubMed
  8. Eur J Pharm Sci. 2005 Apr;24(5):411-9 - PubMed
  9. Nat Rev Drug Discov. 2008 Jan;7(1):21-39 - PubMed
  10. Adv Drug Deliv Rev. 2009 Feb 27;61(2):158-71 - PubMed
  11. Adv Drug Deliv Rev. 2009 Feb 27;61(2):75-85 - PubMed
  12. Mol Imaging Biol. 2011 Dec;13(6):1215-23 - PubMed
  13. Nanomedicine (Lond). 2011 Feb;6(2):365-75 - PubMed
  14. J Control Release. 2012 Feb 10;157(3):455-60 - PubMed
  15. Biomacromolecules. 2011 Nov 14;12(11):4136-43 - PubMed
  16. Adv Drug Deliv Rev. 2012 May 1;64(6):557-70 - PubMed
  17. J Diabetes Sci Technol. 2013 Mar 01;7(2):520-31 - PubMed
  18. Ther Deliv. 2013 Nov;4(11):1443-67 - PubMed
  19. Int J MS Care. 2013 Spring;15(1):36-45 - PubMed
  20. Biologics. 2014 Mar 19;8:107-14 - PubMed
  21. PLoS One. 2014 Apr 22;9(4):e95274 - PubMed
  22. Nat Rev Drug Discov. 2014 Sep;13(9):655-72 - PubMed
  23. Eur J Pharm Biopharm. 2015 Nov;97(Pt A):280-9 - PubMed
  24. Eur J Pharm Biopharm. 2015 Nov;97(Pt A):250-6 - PubMed
  25. Eur J Pharm Biopharm. 2015 Nov;97(Pt A):257-64 - PubMed
  26. Eur J Pharm Biopharm. 2015 Nov;97(Pt A):230-8 - PubMed
  27. J Drug Target. 2015;23(7-8):768-74 - PubMed
  28. Eur J Pharm Biopharm. 2016 Jan;98:76-89 - PubMed
  29. Eur J Pharm Biopharm. 2016 Jan;98:90-7 - PubMed
  30. Int J Pharm Investig. 2016 Jan-Mar;6(1):1-9 - PubMed
  31. Adv Drug Deliv Rev. 2016 Nov 15;106(Pt B):277-319 - PubMed
  32. Saudi Pharm J. 2016 Jul;24(4):413-28 - PubMed
  33. Sci Adv. 2017 Apr 05;3(4):e1601556 - PubMed
  34. Bioorg Med Chem. 2018 Jun 1;26(10):2700-2707 - PubMed
  35. PLoS One. 2017 Jul 31;12(7):e0181748 - PubMed
  36. J Control Release. 2018 May 10;277:165-172 - PubMed
  37. Eur J Pharm Sci. 2019 Feb 1;128:81-90 - PubMed
  38. Pharm Res. 1998 Jan;15(1):66-71 - PubMed

Publication Types